• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Galapagos halts lupus CAR-T program, confirms 100 layoffs so far this year

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Feb 23, 2024 at 10:52: AM
via Galapagos has never been afraid of reworking its pipeline or workforce to face the future. 2022 saw the Belgian biotech pivot to CAR-T therapies and then drop its kidney disease and fibrosis programs—the latter move coinciding with laying off 200 employees.

article source
 




Top Bottom
Back
Quote